Key chemotherapy treatments are known to have a negative impact on cardiovascular health, even leading to heart failure (HF) in some patients.

Liraglutide, a common medication used to treat type 2 diabetes (T2D), is safe to use for heart failure (HF) patients, according to new findings published in the Journal of the American College of Cardiology.

Long-term daily exposure to air pollution carrying fine particulate matter poses a significant risk of all-cause mortality for people with heart failure (HF).

Heart patients with implanted left ventricular assist devices are more likely to both attempt and succeed in committing suicide than other chronically ill patients, according to a study out of France.

Following data supporting their use for heart failure and type 2 diabetes, will sodium-glucose cotransporter 2 inhibitors find a spot in the heart failure armamentarium?

A new analysis of the CASTLE-AF trial has found that catheter ablation for AFib remains effective in a much larger group of heart failure patients, cementing evidence first presented in early 2018.

A small-scale study published in Circulation March 3 has revealed a potential new culprit behind sudden cardiac death in patients with arrhythmogenic right ventricular cardiomyopathy: integrin β1D.

Drugs used to treat opioid use disorder may also be successful in improving the health outcomes of patients admitted to the hospital for injection drug use-associated endocarditis, according to research out of Boston.

A wearable sensor developed by researchers at University of Utah Health and VA Salt Lake City Health Care System has the potential to predict heart failure complications more than a week before they occur.

A 92.6% reduction in the list price of tafamidis—an effective but ultimately unaffordable drug designed to treat transthyretin amyloid cardiomyopathy—would be required to make the medication accessible to the average heart patient, researchers reported in Circulation Feb. 12.

Medtronic and the FDA were both aware of battery and wire connection defects in a now-recalled heart failure pacemaker for over a year before patients developed serious side effects, according to a report published in JAMA Internal Medicine.

Research out of Ireland suggests end-of-life care needs will nearly double over the next three decades, corresponding to an increase of 84% by 2046.